In vitro and in vivo neuroprotective activity of the cardiac glycoside oleandrin from Nerium oleander in brain slice-based stroke models

Journal of Neurochemistry

Volumn 119, Issue 4, 2011, Pages 805-814

  Dunn, Denise E ^a   He, Dong Ning ^a   Yang, Peiying ^b   Johansen, Mary ^b   Newman, Robert A ^b   Lo, Donald C ^a  

^a DUKE UNIVERSITY   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

biolistics; brain slice; cardiac glycoside; Na +, K + ATPase; neuroprotection

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); BETULIC ACID; BETULIN; CARDIAC GLYCOSIDE; DIGOXIN; NERIUM OLEANDER EXTRACT; ODOROSIDE; OLEANDRIGENIN; OLEANDRIN; OLEANOLIC ACID; PBI 05204; UNCLASSIFIED DRUG; URSOLIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOLISTIC TRANSFORMATION; BLOOD BRAIN BARRIER; BRAIN ISCHEMIA; CELL VIABILITY; CENTRAL NERVOUS SYSTEM; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; IN VITRO STUDY; IN VIVO STUDY; MALE; MAXIMUM TOLERATED DOSE; MOUSE; NERIUM; NERIUM OLEANDER; NERVE CELL DEGENERATION; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PYRAMIDAL NERVE CELL;

ANIMALS; ANOXIA; CARDENOLIDES; CARDIAC GLYCOSIDES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION; GLUCOSE; NERIUM; NEUROPROTECTIVE AGENTS; PHYTOTHERAPY; SODIUM-POTASSIUM-EXCHANGING ATPASE; STROKE; TIME FACTORS; TRANSFECTION;

ANIMALIA; NERIUM OLEANDER;

EID: 80054798016     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2011.07439.x     Document Type: Article

References (42)

1. Adams H. P., Jr, del Zoppo G., Alberts M. J., et al. (2007) Guidelines for the Early Management of Adults With Ischemic Stroke: A Guideline From the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Circulation 115, e478-e534.
2. Astrup J., (1982) Energy-requiring cell functions in the ischemic brain. Their critical supply and possible inhibition in protective therapy. J. Neurosurg. 56, 482-497. (Pubitemid 12055035)
3. Besancon E., Guo S., Lok J., Tymianski M., and, Lo E. H., (2008) Beyond NMDA and AMPA glutamate receptors: emerging mechanisms for ionic imbalance and cell death in stroke. Trends Pharmacol. Sci. 29, 268-275.
4. Braithwaite S. P., Schmid R. S., He D. N., et al. (2010) Inhibition of c-Jun kinase provides neuroprotection in a model of Alzheimer's disease. Neurobiol. Dis. 39, 311-317.
5. Cho S., Wood A., and, Bowlby M. R., (2007) Brain slices as models for neurodegenerative disease and screening platforms to identify novel therapeutics. Curr. Neuropharmacol. 5, 19-33. (Pubitemid 46488264)
6. Choi D. W., (1995) Calcium: still center-stage in hypoxic-ischemic neuronal death. Trends Neurosci. 18, 58-60.
7. Clausen T., Van Hardeveld C., and, Everts M. E., (1991) Significance of cation transport in control of energy metabolism and thermogenesis. Physiol. Rev. 71, 733-774.
8. 2+ signaling in CA1 neurons after brief ischemia in gerbils. J. Neurophysiol. 81, 299-306. (Pubitemid 29264177)
9. Cramer S. C., and, Riley J. D., (2008) Neuroplasticity and brain repair after stroke. Curr. Opin. Neurol. 21, 76-82;.
10. Dasgupta A., and, Emerson L., (1998) Neutralization of cardiac toxins oleandrin, oleandrigenin, bufalin, and cinobufotalin by digibind: monitoring the effect by measuring free digitoxin concentrations. Life Sci. 63, 781-788. (Pubitemid 28383727)
11. Dasgupta A., Risin S. A., Reyes M., and, Actor J. K., (2008) Rapid detection of oleander poisoning by digoxin III, a new digoxin assay. Am. J. Clin. Pathol. 129, 548-553.
12. Feigin V. L., Lawes C. M. M., Bennett D. A., Barker-Collo S. L., and, Parag V., (2009) Worldwide stroke incidence and early case fatality reported in 56 population-based studies: a systematic review. Lancet Neurol. 8, 355-369.
13. Fisher M., Feuerstein G., Howells D. W., Hurn P. D., Kent T. A., Savitz S. I., Lo E. H., and for the S. G. (2009) Update of the stroke therapy academic industry roundtable preclinical recommendations. Stroke 40, 2244-2250.
14. Flanagan R. J., and, Jones A. L., (2004) Fab antibody fragments: some applications in clinical toxicology. Drug Saf. 27, 1115-1133. (Pubitemid 39647853)
15. Franklin J. L., and, Johnson Jr E. M., (1992) Suppression of programmed neuronal death by sustained elevation of cytoplasmic calcium. Trends Neurosci. 15, 501-508.
16. Friberg H., and, Wieloch T., (2002) Mitochondrial permeability transition in acute neurodegeneration. Biochimie 84, 241-250.
17. Garlid K. D., Costa A. D. T., Quinlan C. L., Pierre S. V., and, Dos Santos P., (2009) Cardioprotective signaling to mitochondria. J. Mol. Cell. Cardiol. 46, 858-866.
18. Gladstone D. J., Black S. E., and, Hakim A. M., (2002) Toward wisdom from failure: lessons from neuroprotective stroke trials and new therapeutic directions. Stroke 33, 2123-2136. (Pubitemid 34840080)
19. Golstein P., and, Kroemer G., (2007) Cell death by necrosis: towards a molecular definition. Trends Biochem. Sci. 32, 37-43. (Pubitemid 46043552)
20. +-ATPase as a drug target for ischemic stroke, in New Strategies in Stroke Intervention (, Annunziato L., ed.), pp. 129-151. Humana Press, New York.
21. Hardman J. G., Limbird L. E., Milinoff P. B., Ruddon R. W., and, Gilman A. G., (1996) Goodman and Gilman's: The Pharmacological Basis of Therapeutics. McGraw-Hill, New York.
22. Hochachka P. W., (1986) Defense strategies against hypoxia and hypothermia. Science 231, 234-241. (Pubitemid 16160071)
23. Johnson E. M., Jr, Koike T., and, Franklin J., (1992) A "calcium set-point hypothesis" of neuronal dependence on neurotrophic factor. Exp. Neurol. 115, 163-166.
24. Kaplan J. H., (2002) Biochemistry of Na,K-ATPase. Annu. Rev. Biochem. 71, 511-535. (Pubitemid 34800229)
25. Krishnan A., Lopes R., Alexander J., Becker R., and, Goldstein L., (2010) Antithrombotic therapy for ischemic stroke: guidelines translated for the clinician. J. Thromb. Thrombol. 29, 368-377.
26. Lee J.-M., Grabb M. C., Zipfel G. J., and, Choi D. W., (2000) Brain tissue responses to ischemia. J. Clin. Investig. 106, 723-731.
27. Lloyd-Jones D., Adams R. J., Brown T. M., et al. (2010) Heart Disease and Stroke Statistics-2010 Update: A Report From the American Heart Association. Circulation 121, e46-e215.
28. Lo D. C., (1999) Neuronal transfection using particle-mediated gene transfer. Curr. Protoc. Neurosci. 3, 1-12.
29. McGrail K., Phillips J., and, Sweadner K., (1991) Immunofluorescent localization of three Na,K-ATPase isozymes in the rat central nervous system: both neurons and glia can express more than one Na,K-ATPase. J. Neurosci. 11, 381-391.
30. Newman R. A., Yang P., Pawlus A. D., and, Block K. I., (2008) Cardiac glycosides as novel cancer therapeutic agents. Mol. Interven. 8, 36-49. (Pubitemid 351398451)
31. Papadopoulos C. M., Tsai S.-Y., Alsbiei T., O'Brien T. E., Schwab M. E., and, Kartje G. L., (2002) Functional recovery and neuroanatomical plasticity following middle cerebral artery occlusion and IN-1 antibody treatment in the adult rat. Ann. Neurol. 51, 433-441. (Pubitemid 34260773)
32. Pettmann B., and, Henderson C. E., (1998) Neuronal cell death. Neuron 20, 633-647. (Pubitemid 28199044)
33. Prassas I., and, Diamandis E. P., (2008) Novel therapeutic applications of cardiac glycosides. Nat. Rev. Drug Discov. 7, 926-935.
34. Schinkel A. H., (1999) P-Glycoprotein, a gatekeeper in the blood-brain barrier. Adv. Drug Deliv. Rev. 36, 179-194. (Pubitemid 29121971)
35. Schoner W., and, Scheiner-Bobis G., (2007) Endogenous and exogenous cardiac glycosides: their roles in hypertension, salt metabolism, and cell growth. Am. J. Physiol. Cell Physiol. 293, C509-C536. (Pubitemid 47235171)
36. Siddiqui B. S., Begum S., Siddiqui S., and, Lichter W., (1995) Two cytotoxic pentacyclic triterpenoids from Nerium oleander. Phytochemistry 39, 171-174.
37. Stoppini L., Buchs P. A., and, Muller D., (1991) A simple method for organotypic cultures of nervous tissue. J. Neurosci. Methods 37, 173-182.
38. Tsai S.-Y., Papadopoulos C. M., Schwab M. E., and, Kartje G. L., (2011) Delayed anti-Nogo-a therapy improves function after chronic stroke in adult rats. Stroke, 42, 186-190.
39. Tzen J. T. C., Jinn T.-R., Chen Y.-C., Li F.-Y., Cheng F.-C., Shi L.-S., She H. K. H., Chen B. C. M., Hsieh V., and, Tu M.-l., (2007) Magnesium lithospermate B possesses inhibitory activity on Na+,K+-ATPase and neuroprotective effects against ischemic stroke. Acta Pharmacol. Sin. 28, 609-615. (Pubitemid 46691096)
40. Wang J. K., Portbury S., Thomas M. B., Barney S., Ricca D. J., Morris D. L., Warner D. S., and, Lo D. C., (2006) Cardiac glycosides provide neuroprotection against ischemic stroke: discovery by a brain slice-based compound screening platform. Proc. Natl. Acad. Sci. USA 103, 10461-10466. (Pubitemid 44051189)
41. Watts A. G., Sanchez-Watts G., Emanuel J. R., and, Levenson R., (1991) Cell-specific expression of mRNAs encoding Na+,K(+)-ATPase alpha- and beta-subunit isoforms within the rat central nervous system. Proc. Natl. Acad. Sci. USA 88, 7425-7429. (Pubitemid 21915164)
42. Yang P., Menter D. G., Cartwright C., Chan D., Dixon S., Suraokar M., Mendoza G., Llansa N., and, Newman R. A., (2009) Oleandrin-mediated inhibition of human tumor cell proliferation: Importance of Na,K-ATPase alpha subunits as drug targets. Mol. Cancer Therap. 8, 2319-2328.